Clinical Trial Update: Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update exploring addition of the AKT inhibitor ipatasertib to megestrol acetate for recurrent or metastatic endometrial cancers (Phase 1/Phase 2)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Endometrioid Adenocarcinoma

Drugs mentioned

• Megestrol acetate (megestrol acetate)
• ipatasertib (ipatasertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING